NASDAQ listed Hepion Pharmaceuticals merges with Israeli Pharma Two B
NASDAQ-listed Hepion Pharmaceuticals has successfully merged with Israel-based Pharma Two B, marking a significant breakthrough in the global pharmaceutical market.
This merger of the two companies – whose combined value is over USD58 million – brings together Hepion, which has been developing a treatment for chronic liver diseases, and Pharma Two B, which develops innovative drugs for the treatment of Parkinson’s disease.
Sheppard, Mullin, Richter & Hampton LLP acted as U.S. legal adviser of the clinical-stage biopharmaceutical company, Hepion Pharma, while Lipa Meir & Co., with a team led by head of its Healthcare practice, Gary Copelovitz, served as Hepion’s Israeli legal adviser.
Meitar and Goodwin Procter acted as legal advisors to Pharma Two B.
Following the merger’s expected completion in late 2024, Pharma Two B plans to list on NASDAQ and advance its FDA licensing application for its progressive treatment of Parkinson’s.
